New Retina Radio
New Retina Radio

11.10.25

Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLE

Could a biologic that addresses uveitic macular edema (UME) change the treatment landscape for uveitis patients? Rahul Khurana, MD, joins us to review data from the MEERKAT and SANDCAT trials assessing vamikibart (Genentech/Roche) for UME.  And Arshad Khanani, MD, MA, joins us to review the open-label extension study of GATHER2. What effect does avacincaptad pegol (Izervay, Astellas) have 2 years after the initial study was completed? Join us to hear details about these late-breaking presentations from AAO 2025. 

View full description +

MORE EPISODES

11.10.25

Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLE

Rahul Khurana, MD; and Arshad Khanani, MD, MA

11.06.25

AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt Disease

Peter Kaiser, MD; and Michel Michaelides, MD

11.03.25

The Nuts and Bolts of GA Therapy: The Discussions Continue

Charles Wykoff, MD, PhD; Hasenin Al-khersan, MD; and Nakul Singh, MD

10.23.25

Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDR

Allen Ho, MD; and Charles Wykoff, MD, PhD

10.10.25

New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient Care

Niki Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD

10.09.25

The Nuts and Bolts of GA Therapy: The Opening Sessions

Charles Wykoff, MD, PhD; with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD

10.02.25

Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring Vision

John Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD

10.02.25

Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and Photobiomodulation

John Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD

Show More